Epoetin kappa

From WikiMD's Wellness Encyclopedia



Epoetin kappa is a recombinant human erythropoietin (rhEPO) used primarily in the treatment of anemia, particularly anemia associated with chronic kidney disease (CKD) and chemotherapy-induced anemia. It is a glycoprotein that stimulates erythropoiesis, the production of red blood cells, by mimicking the action of endogenous erythropoietin.

Mechanism of Action[edit | edit source]

Epoetin kappa functions by binding to the erythropoietin receptor on erythroid progenitor cells in the bone marrow. This binding activates the JAK2/STAT5 signaling pathway, leading to the proliferation and differentiation of these progenitor cells into mature red blood cells. The increase in red blood cell production helps alleviate the symptoms of anemia, such as fatigue and weakness.

Clinical Uses[edit | edit source]

Epoetin kappa is indicated for:

  • Treatment of anemia in patients with chronic kidney disease, including those on dialysis and those not on dialysis.
  • Treatment of anemia in cancer patients receiving chemotherapy.
  • Reduction of allogeneic blood transfusions in patients undergoing elective, non-cardiac, non-vascular surgery.

Administration and Dosage[edit | edit source]

Epoetin kappa is administered via subcutaneous or intravenous injection. The dosage and frequency depend on the patient's condition, hemoglobin levels, and response to treatment. Regular monitoring of hemoglobin levels is essential to adjust the dosage and avoid potential complications such as hypertension or thromboembolic events.

Side Effects[edit | edit source]

Common side effects of epoetin kappa include:

  • Hypertension
  • Headache
  • Joint pain
  • Nausea
  • Fever

Serious side effects may include:

  • Increased risk of thromboembolic events
  • Pure red cell aplasia (PRCA)
  • Seizures

Contraindications[edit | edit source]

Epoetin kappa is contraindicated in patients with:

  • Uncontrolled hypertension
  • Known hypersensitivity to epoetin kappa or any of its components

Regulatory Status[edit | edit source]

Epoetin kappa is approved for use in several countries and is subject to regulation by health authorities such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Research and Development[edit | edit source]

Ongoing research is focused on optimizing the efficacy and safety of epoetin kappa, as well as exploring its use in other conditions associated with anemia. Studies are also investigating the potential for biosimilar versions of epoetin kappa to provide cost-effective alternatives.

Also see[edit | edit source]

Template:Erythropoiesis-stimulating agents Template:Anemia treatment

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD